Blog

Blog

Drug Target Encyclopedia Series (45) —IL4R

Linkedin

Release Time：

2026-10-27 15:02

 

  

IL-4R is a central receptor in type 2 immune signaling and a clinically validated target in inflammatory disease.

IL-4R mainly refers to the IL-4 receptor alpha chain (IL-4Rα), which participates in receptor complexes for both IL-4 and IL-13. Through these pathways, IL-4Rα regulates Th2 differentiation, IgE production, mucus secretion, tissue inflammation, and other hallmark features of type 2 immunity.

Because IL-4 and IL-13 share IL-4Rα-dependent signaling, targeting this receptor can simultaneously modulate two major cytokine pathways, making IL-4Rα highly relevant in allergic and inflammatory disease research.

IL-4R is highly relevant in:

• Atopic dermatitis
• Asthma
• Chronic rhinosinusitis with nasal polyps
• Eosinophilic esophagitis
• Prurigo nodularis
• Type 2 inflammatory disease research 

Targeting IL-4R in drug development:

1）Monoclonal antibodies – Block IL-4Rα to inhibit both IL-4- and IL-13-mediated signaling.

2）Next-generation biologics – Explore improved dosing, tissue exposure, or combination strategies for type 2 inflammatory diseases.

3）Bispecific approaches – Combine IL-4R-related blockade with other inflammatory pathways to address disease heterogeneity.

4）Functional studies – Evaluate IL-4/IL-13 signaling, STAT6 activation, cytokine responses, and receptor biology.

 

💥 Challenges include:

• Disease heterogeneity
• Biomarker selection
• Variable dependence on IL-4 versus IL-13
• Long-term immune modulation
• Differentiation from other type 2 inflammation targets 

🔬 IL-4Rα remains one of the most important targets in type 2 inflammation.

Its ability to sit at the intersection of IL-4 and IL-13 signaling makes it especially attractive for diseases driven by overlapping allergic and inflammatory pathways.

🔍 Is IL4R part of your immuno-oncology or immune modulation drug discovery pipeline?

 

Fill out the form below, or visit the link: to browse the complete list of available in-stock products.  

 

Prev

No

Drug Target Encyclopedia Series (44) —CD28

Next